Anti-TNF therapy could treat patients suffering from Covid-19-related ARDS

29 May 2020 (Last Updated May 29th, 2020 16:16)

A retrospective study in Wuhan, China, observed that 17% of 99 coronavirus pneumonia patients developed acute respiratory distress syndrome (ARDS). Established anti-tumor necrosis factor (TNF) therapies such as Remicade (infliximab) and Humira (adalimumab) have a proven track record of decreasing inflammation in inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), and could potentially treat coronavirus patients who develop ARDS, due to the inflammatory excess that occurs in patients with Covid-19.

Data from SECURE-IBD, a coronavirus and IBD database, have shown that of 116 patients on anti-TNF therapy who contracted Covid-19, 99 recovered without hospitalisation and one patient died.

To read more, please click here.